KEYMED BIOSCIENCES INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.85 HKD | +1.70% |
|
+10.25% | -33.20% |
| Apr. 12 | Keymed Biosciences Advances Solid Tumors Drug With First Patient Study | MT |
| Mar. 27 | KeyMed Biosciences’ Attributable Loss Widens in 2023 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Keymed Biosciences Inc is a China-based biotechnology company. The Company focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The Company has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company's main products include CM310, CM326 and CMG901.
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
29.86
CNY
Average target price
54.48
CNY
Spread / Average Target
+82.42%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.20% | 1.03B | |
| -0.49% | 103B | |
| +3.31% | 96.73B | |
| +1.66% | 21.31B | |
| -16.16% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.87% | 13.68B | |
| +6.32% | 13.44B | |
| +21.46% | 10.98B |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Keymed Biosciences Chairman, Controlling Shareholder Ups Stake in Firm
